Vaccine & Biological Regulatory Services
Regalliance serves as your integrated regulatory partner, leveraging extensive regulatory affairs expertise to streamline compliance, mitigate administrative queries, and accelerate market access for domestic biological manufacturers and global brand owners.
Vaccine & Biological Regulatory Services
Regalliance serves as your integrated regulatory partner, leveraging extensive regulatory affairs expertise to streamline compliance, mitigate administrative queries, and accelerate market access for domestic biological manufacturers and global brand owners.
Introduction
Vaccines and biological products represent critical categories within public health, requiring stringent multi-tiered regulatory oversight. In India, the import, clinical evaluation, domestic manufacturing, and commercial distribution of drugs and biologicals are governed under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019.
Navigating these intricate statutory pathways requires absolute technical precision, structured dossier assembly, and proactive portal management. Regalliance serves as your integrated regulatory partner, leveraging extensive regulatory affairs expertise to streamline compliance, mitigate administrative queries, and accelerate market access for domestic biological manufacturers and global brand owners.
Definition of Vaccines & Biologicals
Statutory Classification under "New Drug" Parameters
Under the Indian regulatory framework, all biological products and vaccines are legally categorized as “New Drugs”. Pursuant to Rule 2(1)(w) of the New Drugs and Clinical Trials Rules, 2019, a product continues to be classified as a New Drug if it includes:
Vaccines, recombinant Deoxyribonucleic Acid (r-DNA) derived products, living modified organisms, monoclonal antibodies, stem cell-derived products, gene therapeutic products, or xenografts intended to be used as drugs.
Lifecycle Duration: Unlike conventional new chemical entities—which transition out of “New Drug” status after 4 years from the date of Central Licensing Authority (CLA) approval—vaccines, r-DNA biologicals, monoclonal antibodies, and cell/gene therapies remain classified as New Drugs forever.
Distinction: Vaccines vs. Conventional Pharmaceutical Drugs
Biological Origin & Complexity: Conventional small-molecule drugs are synthesized chemically with precise, reproducible molecular structures. In contrast, vaccines are complex biological mixtures produced from living biological systems (e.g., cell cultures, attenuated viruses, mRNA platforms, or recombinant proteins).
Batch Consistency & Characterization: Because biological inputs inherently carry batch-to-batch variability, vaccines require rigorous lot-by-lot characterization, in-process bio-burden testing, and mandatory National Control Laboratory (NCL) testing prior to market release.
Target Population: Vaccines are primarily administered to large, healthy populations (including infants and children) for preventive immunogenicity, demanding significantly lower toxicity thresholds and heightened safety evaluation compared to therapeutic small molecules.
Regulatory Requirements & Pathways
A. Domestic Manufacturer Pathway
1. Manufacturing & Local Distribution Compliance
2. Involved Regulatory Bodies
3. Required Forms & Overview
| Stage / Purpose | Statutory Form Applied | Official Approval / License Received | Regulatory Overview |
|---|---|---|---|
| R&D / Trial Manufacturing | Form CT-10 / Form CT-11 | Permission to Manufacture | Permission to manufacture new drug or vaccine batches for clinical trials, BA/BE studies, and laboratory testing. |
| New API Development | Form CT-12 / Form CT-13 | Form CT-15 | Approval to manufacture unapproved Active Pharmaceutical Ingredients (APIs) for formulation development and clinical trial use. |
| Commercial Manufacturing Approval | Form CT-21 |
Form CT-22 (API) Form CT-23 (Formulation) |
Permission to manufacture pharmaceutical biological formulations for commercial sale and distribution. |
| Biological Plant Licensing | Form 27 | Form 28-D | License to manufacture biological products (including vaccines and blood products) with explicit CLAA endorsement. |
4. Forms & Statutory Government Fees (Manufacturer)
| Application | Government Fee |
|---|---|
| Form CT-10 (Trial Manufacturing Application) | ₹5,000 / Product |
| Form CT-12 / CT-13 (Unapproved API Manufacturing) | ₹5,000 / Product |
| Form CT-04 (Clinical Trial Permission – Phase I) | ₹3,00,000 |
| Form CT-04 (Clinical Trial Permission – Phase II, III & IV) | ₹2,00,000 |
| Form CT-21 (Commercial Manufacturing Permission) | ₹5,00,000 |
How Regalliance Assists Manufacturers
B. Importer Pathway
Role of Authorized Indian Agent (IAA)
Overseas vaccine manufacturers and foreign brand owners cannot directly submit registration or import applications on Indian regulatory portals.
A legally appointed Authorized Indian Agent (IAA) is required through a notarized and apostilled Power of Attorney (POA).
The IAA must possess valid wholesale licenses Form 20B and Form 21B to manage SUGAM portal submissions and assume regulatory responsibility.
Involved Regulatory Bodies
3. Required Forms & Overview
| Purpose | Statutory Form Applied | Official Approval / License Received | Regulatory Overview |
|---|---|---|---|
| Import Test License | Form 11 / Form CT-16 | Form CT-17 / Form 11 Clearance | Authorizes the import of limited quantities of vaccines or biological products for analytical testing, clinical trials, research, or BA/BE studies. |
| Overseas Site & Product Registration | Form 40 | Form 41 Registration Certificate | Registration of the foreign manufacturing facility together with the specific vaccine or biological product intended for import into India. |
| Commercial Import Approval | Form CT-18 |
Form CT-19 (API) Form CT-20 (Formulation) |
New Drug import authorization permitting the commercial sale and distribution of approved biological products in India. |
| Commercial Import License | Form 8 / Form 8A | Form 10 / Form 10A | Final commercial import license for standard biological formulations (Form 10) or Schedule X substances (Form 10A), allowing lawful import and marketing in India. |
4. Forms & Statutory Government Fees (Importer)
| Application | Government Fee |
|---|---|
| Form 40 (Site & Product Registration) |
$10,000 (Manufacturing Plant) $5,000 per Product |
| Form 8 / Form 10 (Commercial Import License) |
₹10,000 (First Product) ₹1,000 per Additional Product |
| Form CT-16 (Import Test License) | ₹5,000 per Product |
| Form CT-18 (Permission to Import New Drug for Sale) | ₹5,00,000 |
| Form 40 Renewal / Re-Registration |
$10,000 (Plant) $5,000 per Product |
| Shelf-Life Extension / Reduction Amendment | $1,800 |
How Regalliance Assists Importers
Digital Regulatory Transformation
Core Features & Objectives
Why Choose Regalliance?
At Regalliance, we specialize in providing premium regulatory consulting services for vaccines, biologicals, biosimilars, recombinant products, blood products, and advanced biologic therapies. Our regulatory experts help manufacturers and importers navigate India's complex regulatory framework while ensuring complete compliance with CDSCO, DCGI, CLAA, WHO-GMP, Schedule M, and other applicable regulatory requirements.
Our Specialized Regulatory Support
Frequently Asked Questions (FAQs)
Frequently Asked Questions
Q1: Why are all vaccines and biological products classified as "New Drugs" in India?
Under Rule 2(1)(w) of the NDCT Rules, 2019, all vaccines and biological products are categorized as "New Drugs" and retain this statutory status indefinitely to ensure continuous regulatory oversight.
Q2: What is the statutory role of an Authorized Indian Agent (IAA)?
Foreign manufacturers cannot directly apply on Indian government portals and must appoint an Authorized Indian Agent (IAA) holding valid Form 20B/21B wholesale licenses to manage registrations and assume regulatory responsibility.
Q3: Which licenses are required for domestic vaccine manufacturing?
Domestic manufacturers require clinical/test permissions under Form CT-11 and CT-15, commercial New Drug permission through Form CT-23, and biological manufacturing approval under Form 28-D from CLAA.
Q4: What is the process for importing commercial vaccines into India?
Importers must obtain a Form 11/CT-16 test license, complete foreign site and product registration through Form 40 and Form 41, and finally secure a commercial import license through Form 10.
Q5: What is the NANDI portal?
NANDI (NOC Approval for New Drug and Inoculation System) is a digital platform developed by DAHD in collaboration with CDSCO to streamline veterinary drug and vaccine NOC approvals.
Q6: How does NANDI integrate with CDSCO systems?
NANDI integrates with the CDSCO SUGAM portal, enabling online dossier submission, application tracking, and single-window regulatory communication.
Q7: What are CDSCO registration fees for overseas biological products?
Under Form 40, the statutory fee is $10,000 for foreign manufacturing site registration plus $5,000 per vaccine product.
Q8: Where are vaccine samples tested in India?
Vaccine test batches undergo quality and safety evaluation at notified laboratories including NIB Noida, NCTL Kasauli, and IVRI for veterinary biological products.
Q9: Are global vaccines exempt from local clinical trials?
Local clinical trials or bridging studies may be required unless CDSCO grants a waiver based on SEC evaluation of global safety and efficacy data.
Q10: How does Regalliance support vaccine and biological compliance?
Regalliance provides Authorized Indian Agent (IAA) services, CTD dossier preparation, SUGAM and NANDI portal management, regulatory submissions, and coordination with government laboratories.